Jean-Michel Revest

This inventor holds 6 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Universitë De Bordeaux, National Institute of Health and Medical Research, Aelis Farma. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Michel Revest. Retrieved from https://idiyas.com/inventor/jean-michel-revest

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 8.4

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

6 out of 227

Universitë De Bordeaux

patents

5 out of 1,853

National Institute of Health and Medical Research

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583884 - 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders (2026-03-24),

2. 12447159 - 3β-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders (2025-10-21),

3. 11484537 - 3β-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders (2022-11-01),

4. 10259839 - 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone (2019-04-16),

5. 10150793 - Antagonists of CB1 receptor (2018-12-11),

6. 10040816 - Antagonists of CB1 receptor (2018-08-07),

Title: Innovations of Jean-Michel Revest

Introduction

Jean-Michel Revest is a notable inventor based in Bordeaux, France. He has made significant contributions to the field of cannabinoid-related disorders through his innovative research and patents. With a total of five patents to his name, Revest's work focuses on the development of specific pregnenolone derivatives for therapeutic applications.

Latest Patents

One of his latest patents is for the compound 3β-(4-methoxybenzyloxy)pregn-5-en-20-one, which is designed for use in the treatment of cannabinoids-related disorders. This invention relates to a specific pregnenolone derivative that has shown potent effects in inhibiting the impact of THC. The compound is effective in both unconditioned and conditioned effects of THC, including THC self-administration and reinstatement in THC-seeking behavior in non-human primates.

Career Highlights

Throughout his career, Jean-Michel Revest has worked with esteemed institutions such as Université de Bordeaux and the Institut National de la Santé et de la Recherche Médicale. His research has been pivotal in advancing the understanding of cannabinoid-related disorders and their treatment options.

Collaborations

Revest has collaborated with notable colleagues, including Pier Vincenzo Piazza and Monique Vallee, contributing to a rich exchange of ideas and research in his field.

Conclusion

Jean-Michel Revest's innovative work in the treatment of cannabinoid-related disorders highlights his significant contributions to medical research. His patents reflect a commitment to advancing therapeutic options for patients affected by these conditions.

Profile summary based on public USPTO records.